Study S000803

A Single Dose Pharmacokinetic Study of LY2189265 in Subjects With Varying Degrees of Hepatic Impairment

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01253304
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 26
Start: 2010-11
Primary completion: 2011-11
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:LY2189265
Results posted: TRUE
Secondary identifiers: OTHER:H9X-EW-GBDO

Registered primary outcomes

Pharmacokinetics: Maximum Observed Concentration (Cmax) [Predose to 336 hours postdose]
Pharmacokinetics: Time of Maximum Concentration (Tmax) [Predose to 336 hours postdose]
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-tlast]) [Predose to 336 hours postdose]
Pharmacokinetics: AUC From Time Zero to Infinity (AUC[0-infinity]) [Predose to 336 hours postdose]
Pharmacokinetics: Apparent Terminal Elimination Half-life (t1/2) [Predose to 336 hours postdose]
Pharmacokinetics: Apparent Total Plasma Clearance (CL/F) [Predose to 336 hours postdose]
Pharmacokinetics: Apparent Volume of Distribution (Vz/F) [Predose to 336 hours postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.